Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation

Madhur K Garg; Paul Weiss; Anand K Sharma; Giridhar R Gorla; Wainwright Jaggernauth; Ravindra Yaparpalvi; John Delrowe; Jonathan J Beitler

doi:10.1016/j.radonc.2004.04.010

Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation

Radiother Oncol. 2004 Nov;73(2):233-6. doi: 10.1016/j.radonc.2004.04.010.

Authors

Madhur K Garg¹, Paul Weiss, Anand K Sharma, Giridhar R Gorla, Wainwright Jaggernauth, Ravindra Yaparpalvi, John Delrowe, Jonathan J Beitler

Affiliation

¹ Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.

PMID: 15542171
DOI: 10.1016/j.radonc.2004.04.010

Abstract

We describe our experience with adjuvant high dose rate brachytherapy (Ir-192) (HDRB) in patients, who failed surgery and post-operative external radiation therapy. The salvage treatment consisted of excision of the keloid and wound closure followed by HDRB (15 Gy in three fractions given on three consecutive business days beginning the day of surgery). At the time of last follow up, 88% (15/17) of the keloids were without any evidence of recurrence.

Publication types

Comparative Study

MeSH terms

Adolescent
Adult
Brachytherapy*
Cohort Studies
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Keloid / diagnosis*
Keloid / therapy*
Male
Middle Aged
Radiotherapy Dosage
Radiotherapy, Adjuvant
Recurrence
Risk Assessment
Severity of Illness Index
Surgical Procedures, Operative / methods
Treatment Failure
Treatment Outcome